Company intelligence / Profile preview

MCMSC-Agitated Solutions

Saint Paul, Minnesota, United Statesrocketreach.co ↗

Ownership: Private
Development stage: Commercial

Overview

The Orbis Microbubble Generator received Health Canada approval in early 2024 and has entered clinical use at major Canadian centers. The company’s novel injectable ultrasound contrast agent, ASI‑02, received FDA IND clearance in April 2025 to begin a multi-center Phase 3 trial assessing safety and efficacy versus standard manual bubble studies. Early results highlight improved workflow efficiency, more consistent microbubbles, better image quality, single operator usability, and potential to improve diagnostic accuracy over traditional methods[2][4][6].

Therapeutic areas: OtherCardiovascular
Modalities: DeviceContrast agent
Industry: Medical Imaging

Beyond the preview

Go deeper on MCMSC-Agitated Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCMSC-Agitated Solutions.

Explore the full profile